RECORD // Company

CG Oncology, Inc.

Built 2026-11-21T23:42:15Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Cg Oncology, Inc. · Ca business · same registered legal name as 'CG Oncology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • CG Oncology, Inc. · Ct business · same registered legal name as 'CG Oncology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • CG Oncology, Inc. · Ctgov · same registered legal name as 'CG Oncology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • CG ONCOLOGY, INC. · Ny corps · same registered legal name as 'CG Oncology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-06 · accession 0001991792-26-000012

ItemValuePeriodFormFiledAccessionReport
Revenue$1,604,0003 months ended 2026-09-3010-Q2026-11-060001991792-26-0000122026-11-21 23:42 UTCReport an error
Net income (loss)$-56,891,0003 months ended 2026-09-3010-Q2026-11-060001991792-26-0000122026-11-21 23:42 UTCReport an error
Cash and cash equivalents$28,247,000at 2026-09-3010-Q2026-11-060001991792-26-0000122026-11-21 23:42 UTCReport an error
Contract liabilities, current$29,000at 2026-09-3010-Q2026-11-060001991792-26-0000122026-11-21 23:42 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001991792
Ticker
CGON
EIN
371611499
CUSIP
156944100
Record ID
sx:sec:0001991792

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-21 23:42 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-18SEC EDGAR company profile2026-11-21 23:42 UTCReport an error
State of incorporationDE2026-11-18SEC EDGAR company profile2026-11-21 23:42 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-21 23:42 UTCReport an error
Business address3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS, TX, 752472026-11-18SEC EDGAR company profile2026-11-21 23:42 UTCReport an error
ExchangesNasdaq2026-11-18SEC EDGAR company profile2026-11-21 23:42 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$4,040,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax2026-11-21 23:42 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-160,995,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 23:42 UTCReport an error
Total assets (at 2025-12-31)$791,592,0002025-12-3110-K, XBRL Assets2026-11-21 23:42 UTCReport an error
Stockholders' equity (at 2025-12-31)$752,602,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 23:42 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$32,490,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 23:42 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-132,346,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 23:42 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$134,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 23:42 UTCReport an error
Long-term debt (at 2025-12-31)$3,000,0002025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-21 23:42 UTCReport an error
Operating lease liabilities (at 2025-12-31)$4,021,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 23:42 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-16)On November 16, 2026, CG Oncology, Inc. (the “Company”) issued a press release entitled “PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC).” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. On November 16, 2026, the Company posted an updated corporate presentation on the Company’s website. A copy of this presentation is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. Investors may also access the presentation by visiting the “Investor Relations” section of the Company’s website…2026-11-16SEC EDGAR 8-K 0001193125-26-462199 (text as filed, excerpt)2026-11-21 23:42 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-16)On November 16, 2026, the Company announced topline data for its Phase 3 PIVOT-006 registrational trial evaluating adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta ≤3 cm non-muscle invasive bladder cancer (“NMIBC”) following complete tumor resection. There are currently no U.S. Food and Drug Administration (“FDA”) approved adjuvant treatment options in this population of approximately 50,000 patients. PIVOT-006 achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus the control arm. Cretostimogene resulted in a 68% reduction in the risk of recurrence compared with the control arm…2026-11-16SEC EDGAR 8-K 0001193125-26-462199 (text as filed, excerpt)2026-11-21 23:42 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-06)On November 6, 2026, CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether…2026-11-06SEC EDGAR 8-K 0001991792-26-000011 (text as filed, excerpt)2026-11-21 23:42 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026, CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made…2026-08-06SEC EDGAR 8-K 0001193125-26-336886 (text as filed, excerpt)2026-11-21 23:42 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-06)On August 6, 2026, the Company filed Amendment No. 2 to Prospectus (the “Amendment No. 2”) with the Securities and Exchange Commission (the “SEC”) for the offer and sale of shares of its common stock, par value $0.0001 per share (the “Shares”), pursuant to that certain Open Market Sale Agreement, dated March 28, 2025, by and between the Company and Jefferies LLC (the “Sale Agreement”), to increase the Shares available to be sold pursuant to the terms of the Sale Agreement by an additional $500.0 million (the “Additional Shares”). The Amendment amends and supplements the information in the prospectus dated March 28, 2025 (the “Prospectus”) filed with the SEC as part of the Company’s…2026-08-06SEC EDGAR 8-K 0001193125-26-336886 (text as filed, excerpt)2026-11-21 23:42 UTCReport an error
Plan (welfare, plan no. 501)CG ONCOLOGY INC HEALTH AND WELFARE PLAN: 142 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 23:42 UTCReport an error
Largest institutional holder #1 (13F as filed): RTW INVESTMENTS, LP$604,961,6202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #2 (13F as filed): Decheng Capital LLC$452,707,0832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$444,509,2642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #4 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP$378,323,5592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #5 (13F as filed): FMR LLC$295,674,0772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #6 (13F as filed): TCG Crossover Management, LLC$260,768,1362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$246,202,2472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #8 (13F as filed): STATE STREET CORP$244,240,7702026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #9 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$235,658,1432026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error
Largest institutional holder #10 (13F as filed): Foresite Capital Management VI LLC$168,358,2332026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:42 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.